Table 2.
All-cause mortality | Breast cancer mortality | Breast cancer recurrence | Progression-free survival | |||||
---|---|---|---|---|---|---|---|---|
Exposure: HR (95%CI) | Refernces | Exposure: HR (95%CI) | References | Exposure: HR (95%CI) | References | Exposure: HR (95%CI) | References | |
Sleep duration | ≤ 6 h: 0.95 (0.80–1.13) | [31] | ≤ 6 h: 0.83 (0.67–1.04) | [31] | ≤ 6 h: 0.93 (0.77–1.12) | [31] | < 6 h: 1.45 (0.83–2.54) | [37] |
≤ 6 h: 1.05 (0.88–1.24) | [32] | ≤ 6 h: 1.13 (0.86–1.48) | [32] | |||||
≤ 6 h consistent: 0.91 (0.73–1.12) | [31] | ≤ 6 h consistent: 0.78 (0.60–1.01) | [31] | ≤ 6 h consistent: 0.93 (0.74 -1.17) | [31] | |||
≤ 6 h inconsistent: 0.79 (0.63–0.98) | [31] | ≤ 6 h inconsistent: 0.80 (0.61–1.06) | [31] | ≤ 6 h inconsistent: 0.82 (0.64–1.06) | [31] | |||
≥ 9 h: 1.43 (1.07–1.92) | [31] | ≥ 9 h: 1.52 (1.09–2.13) | [31] | ≥ 9 h: 1.48 (1.01–2.00) | [31] | > 9 h: 2.33 (1.01–5.42) | [37] | |
≥ 9 h: 1.37 (1.10–1.71) | [32] | ≥ 9 h: 1.46 (1.02–2.07) | [32] | |||||
≥ 9 h consistent: 1.46 (0.97–2.21) | [31] | ≥ 9 h consistent: 1.22 (0.75–1.99) | [31] | ≥ 9 h consistent:1.30 (0.85–1.98) | [31] | |||
≥ 9 h inconsistent: 1.47 (1.12–1.93) | [31] | ≥ 9 h inconsistent: 1.70 (1.23–2.36) | [31] | ≥ 9 h inconsistent: 1.60 (1.18–2.18) | [31] | |||
TIB shorter: 0.99 (0.97–1.00) | [33] | |||||||
≥ 1 h increase (from pre-to post- dx)b: 1.35 (1.04–1.74) | [32] | ≥ 1 h increase (from pre-to post- dx)b: 1.29 (0.84–2.00) | [32] | |||||
≥ 1 h decrease (from pre-to post- dx)b: 1.26 (0.97–1.65) | [32] | ≥ 1 h decrease (from pre-to post- dx)b: 0.89 (0.55–1.45) | ||||||
This section should be white | < 6 h or > 9 h: 2.73 (0.99–7.52)c | [36] | ||||||
Sleep quality | Difficulty: 1.49 (1.02–2.19) | [32] | Difficulty: 1.78 (0.94–3.36) | [32] | ||||
Efficiency (≥ 85%): 0.94 (0.91–0.97) | [33] | Efficiency (< 85%): 1.65 (0.92–2.92) | [37] | |||||
Quality (bad/very bad): 3.08 (1.74–5.47) | [37] | |||||||
Quality poor: 0.78 (0.27–2.29)c | [36] | |||||||
Latency: 0.89 (0.75–1.06) | [33] | |||||||
WASO (min): 0.41 (0.25 -0.67) | [33] | |||||||
WASO (%TST): 0.97 (0.96–0.98) | [33] | |||||||
WE (fewer): 0.93 (0.88 -0.98) | [33] | |||||||
WE duration (shorter): 0.29 (0.14–0.58) | [33] | |||||||
Sleep disorders | 1.39 (1.04–1.87) | [34] | ||||||
Habitual day time napping | 0.94 (0.61–1.44) | [37] | ||||||
Bedtime misalignment d | 3.18 (1.32–7.61) | [38] | ||||||
Nightly fasting | < 13 h: 1.22 (0.95–1.56) | [35] | < 13 h: 1.21 (0.91–1.60) | [35] | < 13 h: 1.36 (1.05–1.76) | [35] | ||
Eating episodes per day | 0.99 (0.89–1.10) | [35] | 1.00 (0.89–1.13) | [35] | 0.97 (0.87–1.08) | [35] | ||
Eating after 8PM | Yes: 0.97 (0.76–1.24) | [35] | Yes: 0.98 (0.74–1.28) | [35] | Yes: 0.97 (0.76–1.24) | [35] |
aTIB Time In Bed; WASO Wake After Sleep Onset; TST Total Sleep Time; WE Wake Episodes
bChanges in sleep duration from pre-post-diagnosis by either ⩾1 h more (increase) or ⩾1 h less (decrease), versus no change
cMeasured relative risk
dDefined as misalignment of preferred (assessed via Morningness-Eveningness Questionnaire) and habitual bedtime [38]